Search Within

Matteo Repetto

  1. "Solid Tumor Oncology Division"
Formats
  1. Meeting Abstract (8)
  2. Review (5)
  3. Journal Article (4)
  4. Editorial (1)
Groups
  1. Department of Medicine (18)
  2. Sloan Kettering Institute Postdocs (18)
  3. Solid Tumor Oncology Division (18)
  4. Thoracic Oncology (15)
  5. Graduate Medical Education (14)
  6. Department of Pathology and Laboratory Medicine (12)

More Groups

People
  1. Alexander Drilon (15)
  2. Andrea Gazzo (6)
  3. Britta Weigelt (6)
  4. Pier Selenica (6)
  5. Mark Donoghue (5)
  6. Soo Ryum Yang (5)

More People

Years
  1. 2025 (2)
  2. 2024 (11)
  3. 2023 (5)
Publications
  1. Journal of Clinical Oncology (4)
  2. Laboratory Investigation (3)
  3. Annals of Oncology (1)
  4. British Journal of Cancer (1)
  5. Cancer (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Nature Publishing Group (4)
  3. Elsevier Inc. (2)
  4. Adis International Ltd (1)
  5. American Association for Cancer Research (1)
  6. John Wiley & Sons (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
    Journal Article

    Roa, P.; Foglizzo, V.; Harada, G.; Repetto, M.; Kulick, A.; de Stanchina, E.; de Marchena, M.; Auwardt, S.; Sayed Ahmed, S.; Bremer, N. V.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
    Journal Article

    Thawani, R.; Repetto, M.; Keddy, C.; Nicholson, K.; Jones, K.; Nusser, K.; Beach, C. Z.; Harada, G.; Drilon, A.; Davare, M. A.
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • NTRK gene fusion testing and management in lung cancer
    Review

    Repetto, M.; Chiara Garassino, M.; Loong, H. H.; Lopez-Rios, F.; Mok, T.; Peters, S.; Planchard, D.; Popat, S.; Rudzinski, E. R.; Drilon, A.; more...
    Cancer Treatment Reviews (2024)

    Fulltext@MSK | Save
  • Amplification of wild-type RET represents a novel molecular subtype of several cancer types with clinical response to selpercatinib
    Journal Article

    Gandhi, M. M.; Ricciuti, B.; Harada, G.; Repetto, M.; Gildenberg, M. S.; Singh, A.; Li, Y. Y.; Gagné, A.; Wang, X.; Aizer, A.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort
    Meeting Abstract

    Repetto, M.; Richards, A. L.; Chen, M. F.; Zhu, Y.; Selenica, P.; Gazzo, A.; Lee, P.; Price, A.; Yang, S. R.; Marra, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • RET-altered cancers—A tumor-agnostic review of biology, diagnosis and targeted therapy activity
    Review

    Desilets, A.; Repetto, M.; Yang, S. R.; Sherman, E. J.; Drilon, A.
    Cancers (2023)

    Fulltext@MSK | Save
  • A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
    Journal Article

    Repetto, M.; Crimini, E.; Belli, C.; Boscolo Bielo, L.; Ascione, L.; Meric-Bernstam, F.; Drilon, A.; Curigliano, G.
    European Journal of Cancer (2023)

    Fulltext@MSK | Save